Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1698927315610.pdf (New Zealand)
Psychoactive Substances Amendment Bill Government Bill Explanatory note General policy statement The Psychoactive Substances Amendment Bill gives effect to the Government’s decision to introduce legislation ending interim prod- uct approvals under the Psychoactive Substances Act 2013 (the prin- cipal Act).
The principal Act addressed the Government’s concerns about the availability of potentially harmful psychoactive substances with lit- tle or no control over their ingredients, potency, place of sale, or pur- chase age.
The specific objectives of the Bill are— • • • to revoke all interim product approvals: to revoke all interim retail and wholesale licences: to require the recall and disposal of all products for which in- terim product approval has been revoked: to suspend, until regulations come into effect, the requirement that Psychoactive Substances Regulatory Authority must con- sider product approvals: to provide that the results of trials that involve the use of ani- mals cannot be used in the assessment of a psychoactive prod- uct.
However, results of trials undertaken overseas can be used • • 206—1 2 • Psychoactive Substances Amendment Bill Explanatory note in the assessment of psychoactive products if the trial shows that a psychoactive product would pose more than a low risk of harm to individuals using the product: to provide that no compensation is payable by the Crown for any loss or damages as a result of the amendments.
Departmental disclosure statement The Ministry of Health is required to prepare a disclosure statement to assist with the scrutiny of this Bill.

It provides access to informa- tion about the policy development of the Bill and identifies any sig- nificant or unusual legislative features of the Bill.

A copy of tion.govt.nz/disclosure.aspx?type=bill&subtype=govern- ment&year=2014&no=206&.
the statement can be found at http://legisla- Regulatory impact statement The Ministry of Health produced a regulatory impact statement on 2 May 2014 to help inform the main policy decisions taken by the Government relating to the contents of this Bill.
A copy of this regulatory impact statement can be found at— • http://www.health.govt.nz/about-ministry/legislation-and- regulation/regulatory-impact-statements http://www.treasury.govt.nz/publications/informationre- leases/ris • Clause by clause analysis Clause 1 is the Title clause.

Clause 2 is the commencement clause.

It provides that the Bill comes into force on the day after the date on which it receives the Royal assent.
Clause 3 provides that the Bill amends the Psychoactive Substances Act 2013 (the principal Act).

Clause 4 amends section 4, which sets out principles that are to be taken into account in the performance of functions or duties or the exercise of powers under the principal Act.

Clause 4 adds, as a prin- ciple, that animals must not be used in trials for the purposes of as- sessing whether a psychoactive product should be approved.
Explanatory note Psychoactive Substances Amendment Bill 3 Clause 5 amends section 6, which sets out an overview of the princi- pal Act, by repealing the subparagraph that refers to the sale of psy- choactive products on an interim basis.
Clause 6 replaces section 12, which currently restricts the type of trials involving animals to which the Psychoactive Substances Expert Advisory Committee (the advisory committee) may have regard in evaluating psychoactive products and giving advice on the products to the Psychoactive Substances Regulatory Authority (the Author- ity).

New section 12(1) provides that the advisory committee must not have regard to the results of any trial that involves the use of an ani- mal.
New section 12(2) provides that the advisory committee may have regard to the results of a trial undertaken overseas if the committee considers that the trial shows that a psychoactive product would pose more than a low risk of harm to individuals using the product.
This is to ensure that, if information from trials undertaken overseas involv- ing animals is available and the information shows a product would pose more than a low risk of harm to individuals, the advisory com- mittee can use that information to protect the health of individuals by recommending that a product not be approved.
Section 33(3) of the principal Act provides that applications for ap- proval of psychoactive products must not include particulars, infor- mation, documents, or other material that the advisory committee must not have regard to under new section 12.

The effect of section 33(3), after the commencement of new section 12, is that the results of any trial involving animals must not form part of the information provided to the Authority in support of an application for approval of a psychoactive product.
The exception is information from a trial undertaken overseas where the trial shows that a product poses more than a low risk of harm to individuals.

Clause 7 amends section 37 of the principal Act to impose a similar restriction on the information that the Authority may have regard to in deciding whether to approve a product.
New subsection (3) provides that the Authority must not, in deciding whether to approve a product, have regard to any particulars, information, documents, or other material that the advisory committee must not have regard to under new section 12.

4 Psychoactive Substances Amendment Bill Explanatory note The effect of new section 37(3) is that the Authority must not have regard to the results of any trial involving animals when deciding whether or not to approve a psychoactive product.
The exception is information from a trial undertaken overseas where the trial shows that a product poses more than a low risk of harm to individuals.

In summary, the principal Act, once amended, will effectively pro- vide that a trial involving animals cannot be used to support an appli- cation for approval of a psychoactive product.

If a person intended to carry out such a trial in New Zealand regardless, it is expected that the trial would require approval under the Animal Welfare Act 1999.
In the absence of such approval, carrying out the trial would be in breach of that Act and the penalties provided in that Act would apply.

Clause 7 also amends section 37 to provide, for the avoidance of doubt, that if the Authority is unable to satisfy itself that a psychoac- tive product poses no more than a low risk of harm, the Authority must refuse to approve the product.
Clause 8 provides that Schedule 1 of the principal Act, which deals with interim approval of products and the issue of interim licences, is amended as set out in the Schedule of the Bill.
The amendments to Schedule 1 are as follows: • some references to interim approvals of psychoactive prod- ucts, and to such products approved on an interim basis, are removed: clauses 3 to 6, which provided for applications for and grants and duration of interim approvals, are repealed: clause 8 is amended to clarify that the provisions of subparts 1 and 3 of Part 2 of the principal Act apply to interim licences granted under Schedule 1: new clause 11 revokes every interim approval of a psychoac- tive product: new clause 12 provides that the Authority must, before the close of the day after the date of the commencement of that clause, issue a recall order under section 88 in respect of the products: new clause 13 revokes every interim licence to sell psychoac- tive products with interim approval: new clause 14 confirms that interim licences to sell psychoac- tive products granted interim approval (by retail or wholesale) • • • • • • Explanatory note Psychoactive Substances Amendment Bill 5 and interim approvals of products may not be granted, regard- less of the outcome of any extant appeal under subpart 3 of Part 2: new clause 15 preserves, until the close of the 14th day after the date of the commencement of the Bill and for the purpose of the recall under clause 12, the powers of entry and search under section 78 in relation to the holders of interim licences for the sale of psychoactive products with interim approval (despite the revocation of those interim licences under clause 13): new clauses 16 and 17 impose a moratorium on the Authority processing— • applications for licences under section 13 until regula- tions relating to licence applications come into force: applications for approvals of psychoactive products under section 33 until regulations relating to applica- tions for product approval come into force: • new clause 18 provides that no compensation or damages are payable by the Crown for any loss or damage arising from the enactment of the Bill.
• • • Hon Peter Dunne Psychoactive Substances Amendment Bill Government Bill Contents Title Commencement Principal Act Section 4 amended (Principles) Section 6 amended (Overview) Section 12 replaced (Duty of advisory committee relating to use of animals when evaluating psychoactive products) Advisory committee not to have regard to results 12 of trials involving animals Section 37 amended (Grounds for approving product) Schedule 1 amended Schedule Amendments to Schedule 1 of principal Act Page 1 2 2 2 2 2 2 2 3 4 The Parliament of New Zealand enacts as follows: 1 Title This Act is the Psychoactive Substances Amendment Act 2014.
206—1 1 cl 2 Psychoactive Substances Amendment Bill Commencement This Act comes into force on the day after the date on which it receives the Royal assent.

Principal Act This Act amends the Psychoactive Substances Act 2013 (the 5 principal Act).

Section 4 amended (Principles) After section 4(e), insert: “(f) animals must not be used in trials for the purposes of assessing whether a psychoactive product should be ap- 10 proved.” Section 6 amended (Overview) Repeal section 6(1)(c)(ix).
Section 12 replaced (Duty of advisory committee relating to use of animals when evaluating psychoactive products) Replace section 12 with: 15 “12 Advisory committee not to have regard to results of trials “(1) involving animals In performing the function set out in section 11(2)(a), the ad- visory committee must not have regard to the results of a trial 20 that involves the use of an animal.
“(2) However, the advisory committee may have regard to the re- sults of a trial undertaken overseas that involves the use of an animal if the advisory committee considers that the trial shows that the psychoactive product would pose more than a low risk 25 of harm to individuals using the product.” 7 Section 37 amended (Grounds for approving product) In section 37, insert as subsections (2) and (3): “(2) To avoid doubt, if the Authority is unable to satisfy itself of the matter in subsection (1)(b), the Authority must refuse to 30 approve a psychoactive product as an approved product.
In deciding whether or not to approve a psychoactive product as an approved product, the Authority must not have regard “(3) 2 Psychoactive Substances Amendment Bill cl 8 to any particulars, information, documents, or other material relating to any trial that the advisory committee must not have regard to under section 12.” 8 Schedule 1 amended Amend Schedule 1 as set out in the Schedule of this Act.
5 3 Schedule Psychoactive Substances Amendment Bill Schedule Amendments to Schedule 1 of principal Act s 8 Clause 1 In clause 1, replace the definition of full application with: “full application means, in respect of an activity to which an 5 interim licence relates, an application made under section 13 by the person who was granted the interim licence”.
In clause 1, replace the definition of interim approval with: “interim approval means an approval of a psychoactive prod- uct granted by the Authority under clause 4 before that clause 10 was repealed by section 8 of the Psychoactive Substances Amendment Act 2014”.

Clause 2 In clause 2(1), replace “This schedule applies” with “Clauses 1 to 15 of this schedule apply”.
Replace clause 2(2) with: “(2) A psychoactive substance to which this schedule applies may continue to be imported, manufactured, researched, or sold after the commencement of this Act, but only by a person who holds an interim licence and while that licence remains 20 in force.” 15 Cross-heading above clause 3 Repeal the cross-heading above clause 3.

Clauses 3 to 6 Repeal clauses 3 to 6.

Clause 7 Repeal clause 7(1)(e) and (f).
25 4 Psychoactive Substances Amendment Bill Schedule Clause 8 Replace clause 8 with: “8 Application of subparts 1 and 3 of Part 2 to interim licence Subparts 1 and 3 of Part 2 (except sections 13 and 16(1)(a)) apply, with any necessary modifications,— “(a) to an application for an interim licence as if it were an application made under section 13; and to an interim licence granted in accordance with para- graph (a).” “(b) 5 10 delete “an application for interim approval or”: replace “approval or licence” with “licence”.
Clause 10 In the heading to clause 10, delete “interim approval or”.

In clause 10,— (a) (b) In clause 10, in the table, replace the heading to the first column with 15 “Interim licence”.

In clause 10, in the table, repeal the items relating to— interim approval of psychoactive product: (a) interim licence to sell psychoactive products granted interim (b) approval by retail: interim licence to sell psychoactive products granted interim approval by wholesale.
(c) 20 New cross-headings and clauses 11 to 18 After clause 10, insert: “Interim approvals of psychoactive products and interim licences to sell psychoactive products granted interim approval revoked 25 “11 Revocation of interim approvals of psychoactive products Every interim approval granted in respect of a psychoactive product under clause 4 (before that clause was repealed by 30 section 8 of the Psychoactive Substances Amendment Act 2014) is revoked.
“12 Recall of interim approved products “(1) The Authority must, before the close of the day after the date of the commencement of this clause, issue a recall order under 35 5 Schedule Psychoactive Substances Amendment Bill New cross-headings and clauses 11 to 18—continued section 88 for every psychoactive product described in clause 11 (the product).
“(2) The Authority must— “(a) display the date of the recall order prominently on the recall order; and 5 “(b) notify the recall order on an Internet site maintained by or on behalf of the Authority.

“(3) For the purposes of section 88(2), the recall order is deemed to have been received by every importer, manufacturer, whole- saler, or retailer of the product on the close of the day after the 10 date displayed on the recall order.
“(4) The recall order may— “(a) require every importer, manufacturer, wholesaler, and retailer (or any combination of them) to— “(i) provide information to the Authority in relation 15 to the amount and type of the product in their possession: “(ii) dispose of or destroy, or arrange for the disposal (including by return to a manufacturer or an im- porter) or the destruction of, the product in their 20 possession: “(iii) provide information to the Authority on the dis- posal of or destruction or arrangements for the disposal or destruction of the product in their pos- session: 25 “(b) specify locations where the product can be delivered for disposal or destruction: specify a time limit for compliance with the recall order: specify any ancillary or incidental requirement.
“(5) For the avoidance of doubt, section 88(2) and (3) applies to 30 “(c) “(d) the recall order issued in accordance with this clause.
It is a defence to a charge of an offence specified in subclause (7) that the action or omission that constitutes the offence was done— “(a) in good faith in the course of complying with the recall 35 order; and “(6) 6 Psychoactive Substances Amendment Bill Schedule New cross-headings and clauses 11 to 18—continued “(b) within 14 days after the date of the commencement of this clause.
“(7) The offences to which the defence in subclause (6) may apply are— “(a) “(b) “(c) an offence under section 28: an offence under section 70: an offence under section 71.

5 “13 Revocation of interim licences to sell psychoactive products granted interim approval “(1) Every interim licence granted under clause 7(1)(e) and (f) (be- 10 fore those paragraphs were repealed by section 8 of the Psy- choactive Substances Amendment Act 2014) is revoked.
“(2) Despite the revocation of interim licences under subclause (1), a wholesaler or retailer who held an interim licence im- mediately before this clause came into force— “(a) must comply with the recall order issued in accordance with clause 12 as if the wholesaler or retailer continued to hold the licence; and is, for the purposes of section 88, to be treated as if it continued to hold the licence until the close of the 14th 20 day after the commencement of this clause.
“(b) 15 “14 Appeals under subpart 3 of Part 2 For the avoidance of doubt, and regardless of the outcome of any appeal under subpart 3 of Part 2, the following may not be granted after the commencement of the Psychoactive Sub- 25 stances Amendment Act 2014: “(a) an interim licence to sell psychoactive products granted interim approval by retail: an interim licence to sell psychoactive products granted interim approval by wholesale: an interim approval.
“(b) “(c) 30 7 Schedule Psychoactive Substances Amendment Bill New cross-headings and clauses 11 to 18—continued “Enforcement powers “15 Power to enter and search retail premises “(1) This clause applies in relation to the retail premises of every holder of an interim licence granted under clause 7(1)(e) (before that paragraph was repealed by section 8 of the 5 Psychoactive Substances Amendment Act 2014) and revoked by clause 13.
“(2) An enforcement officer or a constable may, for the purpose of ensuring or enforcing compliance with the recall order issued in accordance with clause 12, exercise any powers under sec- 10 tion 78 in relation to those retail premises until the close of the 14th day after the date of the commencement of this clause as if the interim licence concerned had not been revoked.

“(3) Section 78, as modified by subclause (2), applies in relation to those retail premises.
15 “Moratorium on processing applications under section 13 or 33 until regulations in force “16 Moratorium on processing applications for licences under section 13 “(1) The Authority must not process any application for a licence 20 of a kind described in section 13(1)(a) to (d) (whether the ap- plication is made before or after the commencement of this clause) until regulations under section 95 prescribing the fees or charges for applications for licences of that kind come into force.
25 “(2) The Authority must not process any application for a licence of a kind described in section 13(1)(e) or (f) (whether the ap- plication is made before or after the commencement of this clause) until both of the following have come into force: “(a) regulations under section 95 prescribing the fees or 30 charges for applications for licences of that kind; and regulations under section 101(1)(a) prescribing the par- ticulars, information, documents, samples, or other ma- terial that must accompany or be contained in applica- tions for licences of that kind.
35 “(b) 8 Psychoactive Substances Amendment Bill Schedule New cross-headings and clauses 11 to 18—continued “17 Moratorium on processing applications for approval of psychoactive product under section 33 The Authority must not process any application for approval of a psychoactive product under section 33 (whether the ap- plication is made before or after the commencement of this 5 clause) until both of the following have come into force: “(a) regulations under section 95 prescribing the fees or charges for applications for approval of psychoactive products; and regulations under section 101(1)(a) prescribing the par- 10 ticulars, information, documents, samples, or other ma- terial that must accompany or be contained in applica- tions for approval of psychoactive products.
“(b) “No compensation or damages “18 No compensation or damages 15 No compensation or damages are payable by the Crown for any loss or damage arising from the enactment of the Psy- choactive Substances Amendment Act 2014.” 12 Wellington, New Zealand: Published under the authority of the New Zealand Government—2014 9